- Home
- SCPH vs VTYX Comparison
SCPH vs VTYX Comparison
Compare SCPH & VTYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCPH
- VTYX
- Stock Information
- Founded
- SCPH 2013
- VTYX 2018
- Country
- SCPH United States
- VTYX United States
- Employees
- SCPH N/A
- VTYX N/A
- Industry
- SCPH Biotechnology: Pharmaceutical Preparations
- VTYX Medicinal Chemicals and Botanical Products
- Sector
- SCPH Health Care
- VTYX Health Care
- Exchange
- SCPH Nasdaq
- VTYX Nasdaq
- Market Cap
- SCPH 173.6M
- VTYX 154.9M
- IPO Year
- SCPH 2017
- VTYX 2021
- Fundamental
- Price
- SCPH $3.25
- VTYX $1.61
- Analyst Decision
- SCPH Strong Buy
- VTYX Buy
- Analyst Count
- SCPH 2
- VTYX 4
- Target Price
- SCPH $15.00
- VTYX $11.33
- AVG Volume (30 Days)
- SCPH 267.8K
- VTYX 1.3M
- Earning Date
- SCPH 03-12-2025
- VTYX 03-04-2025
- Dividend Yield
- SCPH N/A
- VTYX N/A
- EPS Growth
- SCPH N/A
- VTYX N/A
- EPS
- SCPH N/A
- VTYX N/A
- Revenue
- SCPH $30,278,000.00
- VTYX N/A
- Revenue This Year
- SCPH $172.27
- VTYX N/A
- Revenue Next Year
- SCPH $131.75
- VTYX N/A
- P/E Ratio
- SCPH N/A
- VTYX N/A
- Revenue Growth
- SCPH 303.87
- VTYX N/A
- 52 Week Low
- SCPH $3.08
- VTYX $1.57
- 52 Week High
- SCPH $6.54
- VTYX $11.48
- Technical
- Relative Strength Index (RSI)
- SCPH 43.27
- VTYX 34.49
- Support Level
- SCPH $3.09
- VTYX $1.57
- Resistance Level
- SCPH $3.87
- VTYX $1.78
- Average True Range (ATR)
- SCPH 0.20
- VTYX 0.10
- MACD
- SCPH 0.00
- VTYX -0.00
- Stochastic Oscillator
- SCPH 20.65
- VTYX 10.26
About SCPH scPharmaceuticals Inc.
scPharmaceuticals Inc is a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care and reduce healthcare costs. The company's main product is Furoscix. Furoscix consists of this patented formulation of furosemide for subcutaneous administration with wearable, portable sc2Wear Infusor for the treatment of edema in patients with heart failure.
About VTYX Ventyx Biosciences Inc.
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.